Table 3.
Surgical characteristics and endpoints of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.
| Variable | Surgery (n=23) |
|---|---|
| R0 resection, n (%) | 22 (95.7) |
| Adjuvant chemotherapy, n (%) | 21 (91.3) |
| Type of surgery, n (%) | |
| Lobectomy | 16 (69.6) |
| Bilobectomy | 3 (13.0) |
| Pneumonectomy | 4 (17.4) |
| pCR 1*, n (%) | 2 (8.7) |
| pCR 2**, n (%) | 2 (8.7) |
| MPR, n (%) | 8 (34.8) |
| Downstage, n (%) | 11 (47.8) |
MPR – major pathological response; pCR – pathological complete response; R0 – margin-free.
*
pCR 1 represented the proportion of patients with pCR when considering the tumor only;
**
pCR 2 represented the proportion of patients with pCR when considering the tumor and lymph nodes.